Objective: To evaluate risk factors for acute respiratory disease hospitalizations in children under one year of age.
Methods: A case-control study was conducted in the city of Pelotas, Southern Brazil. Cases were children under one year of age who were hospitalized due to acute respiratory diseases from August 1997 to July 1998. Controls were same-age community children randomly selected without previous respiratory disease hospitalization. A questionnaire about risk factors exposure was applied to the mothers of cases and controls. Univariate, bivariate and multivariate analyses through logistic regression were carried out to evaluate risk factors for the outcome of interest.
Results: There were studied 777 children; 625 cases and 152 controls. In the crude analysis, the risk factors associated with the outcome were: being male, children under six months of age, household crowding, maternal education, family income, inadequate housing conditions, lack of breastfeeding, maternal smoking, use of pacifiers, and a previous history of hospitalization and respiratory symptoms. Maternal working was a protection factor associated with acute respiratory disease hospitalizations. In the multivariate analysis the following risk factors remained associated: maternal education (OR=12.5), previous history of wheezing (OR=7.7), lack of breastfeeding (OR=2.3), use of pacifiers (OR=1.9), maternal smoking (OR=1.7), children under six months of age (OR=1.7), and being male (OR=1.5).
Conclusions: The study results show the importance of the family's social and behavioural aspects as well as previous respiratory disease as risk factors for acute respiratory disease hospitalizations in children under one year of age.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s0034-89102007000300005 | DOI Listing |
Front Biosci (Landmark Ed)
January 2025
Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China.
Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use.
View Article and Find Full Text PDFBr J Hosp Med (Lond)
January 2025
Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Epidemiological studies indicate that the involvement of the immune system in the pathogenesis of infections associated with chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung disease (ILD) remains unclear. This study aims to assess the potential causal link between infections associated with COPD, asthma, or ILD and immune system function. We conducted a two-sample Mendelian randomization analysis using publicly available genome-wide association study (GWAS) datasets.
View Article and Find Full Text PDFBr J Hosp Med (Lond)
January 2025
Department of Pediatrics, Huoqiu First People's Hospital, Lu'an, Anhui, China.
Lobar pneumonia is an acute inflammation with increasing incidence globally. Delayed treatment can lead to severe complications, posing life-threatening risks. Thus, it is crucial to determine effective treatment methods to improve the prognosis of children with lobar pneumonia.
View Article and Find Full Text PDFExpert Opin Biol Ther
January 2025
State Key Laboratory of Respiratory Disease, Joint International Research Laboratory of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
Introduction: Clinical experience with anti-interleukin (IL)-5 biologic therapies for severe asthma has been increasing, alongside deeper and broader research focusing on the role of IL-5 and the IL-5 targeted mepolizumab. This review aims to provide an update of the evidence on the role of IL-5 and mepolizumab, with discussions of the benefits of mepolizumab and its future potential, to promote the comprehension of the pathophysiology and therapeutic approaches to asthma.
Areas Covered: For this narrative review, we conducted a database search in PubMed and Embase using the keywords 'IL-5' and 'mepolizumab,' focusing on randomized controlled trials and real-world studies up to September 2024.
Cancer Med
February 2025
Pulmonology and Thoracic Oncology Department, APHP Hôpital Tenon and Sorbonne Université, Paris, France.
Background: Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.
Methods: A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!